Bonraybio (邦睿生技) announced December revenue of NT$31.38 million (+29.39% YoY), marking a monthly record. Total annual revenue broke the NT$300 million barrier to reach **NT$306 million (+37.43% YoY)**.

Growth Catalysts:

• Product Cycle: The launch of the X3 PRO automated sperm quality analyzer has triggered a replacement wave for the older X1 PRO models. The device uses AI to provide standardized routine sperm data in just three steps and one minute.
• Strategic Re-positioning: As the company celebrates its 10th anniversary, it is expanding from "Male Infertility Total Solutions" to "AI-Powered Fertility Science."
• Female Fertility Market: Bonraybio is now developing technologies for oocyte (egg) cryopreservation and thawing. By optimizing the manual handling process, the company aims to improve egg survival rates and simplify laboratory workflows in reproductive centers.

CEO Dr. Hsu Chen-teng expressed confidence that the integration of AI into both male and female reproductive health will sustain the company's growth momentum through 2026.

Resource: 邦睿生技-創去年12月、全年營收同創高，雙引擎2026年成長續航